MYC and neoplasm: Azacytidine alternated with ITF‐2357 increases IFN‐α/β pathway activation via induction of endogenous retroviruses in non‐small cell lung cancer, potentially leading to expression of cytokines that activate tumor myeloid and T cells; in addition, this epigenetic therapy downmodulates lung cancer MYC mRNA expression to contribute to slowed tumor growth [24].